OPTIMIZE study reports lowest TLR ever achieved in an Investigational Device Exemption (IDE) study with Svelte Medical System’s bioresorbable coated drug-eluting coronary stent
OPTIMIZE Pivotal Study 1 Year Outcomes Announced at TCT Connect NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–The Svelte® Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study. Primary and